dosage of viagra for daily use Parkinson’s permax heart valve disease parkinson’s permax heart valve disease information. Recent studies have revealed permax heart valve disease problems in parkinson’s patients following long-term use of the drug. Since permax was approved in 1988, 12,000 to 25,000 patients have been prescribed the drug to treat the symptoms associated with parkinson’s. Permax is primarily used to treat parkinson’s patients during the early stages of the disease. Recent studies have revealed permax heart valve disease problems in parkinson’s patients following long-term use of the drug. Men and women are affected by parkinson’s disease in almost equal numbers. Parkinson’s disease is the most commonly diagnosed neurodegenerative disorder after alzheimer’s. According to the national institute of neurological disorders and stroke, around 50,000 new parkinson’s disease cases are reported annually. buy cheap viagra viagra for sale viagra for sale cheap viagra without a doctor prescription cheap viagra viagra online viagra without a doctor prescription generic viagra buy viagra viagra for sale Since its approval doctors have prescribed permax to over 500,000 parkinson’s and restless legs syndrome patients. Parkinson’s symptoms are characterized in four primary ways: * rest tremor of a limb (shaking with the limb at rest) * rigidity (stiffness of the limbs and trunk) * slowness of movement (bradykinesia) * postural instability (poor balance) permax (peroglide) is a member of a class of drugs referred to as dopamine agonists and is used to help treat symptoms of parkinson’s disease. Most parkinson’s symptoms are caused by a lack of dopamine. Medications such at permax are used to treat parkinson’s by attempting to mimic dopamine which helps improve the symptoms associated with parkinson’s disease. Recent studies have shown an increased risk of permax heart valve disease in parkinson’s patients who have taken the drug over a long period of time. A new permax study, “cardiac valve regurgitation with peroglide compared with nonergot agonists in parkinson disease”, was published in the march 2007 issue of the medical journal archives of neurology. This study involved parkinson’s patients and showed an increased risk of permax heart valve disease following long-term use of the drug. Two other permax studies conducted in britain and italy also revealed a significant increase in parkinson’s patients developing.